Eli Lilly-backed ophthalmic technology developer Avedro has filed for an $86.3m initial public offering having previously raised $220m in debt and equity financing.
Avedro, a US-based ophthalmic medical technology provider backed by pharmaceutical firm Eli Lilly, has filed to raise up to $86.3m in an initial public offering on the Nasdaq Global Market.
Founded in 2002, Avedro has created a system intended to treat corneal ectatic disorders and correct refractive issues through a combination of ultraviolet light and a riboflavin drug formulations. It made an $18.7m net loss in the first nine months of 2018 from $19.5m in revenue.
The IPO proceeds…
